Accelerate Diagnostics Stock News

Accelerate Diagnostics Inc. (AXDX) Q4 2023 Earnings Call Transcript

Accelerate Diagnostics (AXDX) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to loss of $1.40 per share a year ago.

Accelerate Diagnostics' (AXDX) Arc system eliminates the need for overnight culture incubation, drastically reducing the wait time for identification results.

Accelerate Diagnostics (AXDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earni

Accelerate Diagnostics (AXDX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further streng

Accelerate Diagnostics (AXDX) came out with a quarterly loss of $2.36 per share versus the Zacks Consensus Estimate of a loss of $1.50. This compares to loss of $2.40 per share a year ago.

Here is how Accelerate Diagnostics (AXDX) and BellRing Brands (BRBR) have performed compared to their sector so far this year.

Here is how Accelerate Diagnostics (AXDX) and Cognition Therapeutics, Inc. (CGTX) have performed compared to their sector so far this year.

Accelerate Diagnostics, Inc. (NASDAQ:AXDX ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Laura Pierson - Investor Relations Jack Phillips - President & Chief Executive

Accelerate Diagnostics (AXDX) came out with a quarterly loss of $0.17 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.25 per share a year ago.

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Disney (DIS), Casey's General Stores (CASY), OpGen (OPGN), Accelerate Diagnostics (AXDX) and Nekt

Accelerate Diagnostics (AXDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Accelerate Diagnostics, Inc. (NASDAQ:AXDX ) Q4 2022 Earnings Conference Call March 29, 2023 4:30 PM ET Company Participants Laura Pierson - IR Jack Phillips - President and CEO Steve Reichling - outgo

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 12.50% and 0.93%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stoc

Gainers Dermata Therapeutics, Inc. (NASDAQ: DRMA) shares jumped 121% to $0.4428 after the company requested to withdraw its registration on Form S-1 and said it does not intend to pursue the contempl